Anavex Life Sciences Corp. announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®?3-71 first-in-human study which achieved its cardiovascular safety objectives. The publication is entitled, 'Concentration-QTc Relationship from a Single Amending Dose Study of ANAVEX®?

3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease'. The publication reports the cardiodynamic evaluation part of the single ascending dose study in healthy participants with the primary objective of assessing the effect of ANAVEX®®?3-71 on ECG (electrocardiogram) parameters. The results from this cardiodynamic evaluation demonstrated that ANAVEX®?

three-71 at single ascending doses of 5 to 200 mg had no clinically relevant effects on any of the studied ECG parameters and hence confirmed the ANAVEX®®®?3-71 preclinical cardiovascular safety findings. These data also expand the safety objectives met in this first-in-human study of ANAVEX®??3-71, further supporting its drug development program.